Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 13

Explainer

GLP-1s and unapproved peptides: review

Why a clinician or pharmacist needs the full product list before assessing prescription drugs, GLP-1 medicines and unapproved peptides.

1 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Retatrutide vs semaglutide: the trial

Lilly's reported TRANSCEND-T2D-2 results put retatrutide ahead of semaglutide on average HbA1c and weight change, with important limits.

1 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

TMSB4X and Glioma Spread: Study

A preclinical study linked oligodendrocyte-derived thymosin beta-4 to glioma invasion, without testing a human therapy or a TB-500 product.

1 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

BPC-157 Liver Review: Evidence Limits

A 2026 narrative review summarized broad rodent findings for BPC-157 but provided no controlled evidence of efficacy in human liver disease.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

CagriSema in Type 2 Diabetes: Meta-Analysis

A 2026 Bayesian meta-analysis found clear benefits versus placebo, but the added HbA1c effect versus dose-matched semaglutide was uncertain.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 After Heart Transplant: Study

A 14-center retrospective study found improved metabolic markers in selected heart transplant recipients, without proving comparative benefit or graft safety.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Oral Health Signals: FAERS

A 2026 FAERS analysis found oral-health reporting signals for five GLP-1 medicines, but it could not estimate patient risk or prove causation.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

BPC-157 and TB-500 in Orthopaedics

A 2026 review found preclinical signals but no controlled human orthopaedic efficacy evidence for BPC-157, thymosin beta-4 or TB-500.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide and Alcohol Withdrawal in Rats

A 2026 rat study reported less alcohol intake and anxiety-like behavior, but it does not establish treatment of alcohol use disorder in people.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide Panic Attacks: FAERS Readout

A 2026 FAERS analysis found an adjusted reporting signal, but timing and evidence from other designs did not support a consistent causal link.

28 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Semaglutide in Hemodialysis Study

A 2026 target-trial emulation associated semaglutide with lower mortality and hospitalization than pooled comparators, without proving causation.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide Use in Germany: Database Study

An early German utilization study described who started tirzepatide and recorded dose patterns, without testing effectiveness or a preferred dose.

28 Oct 2026 · PeptideMethods Editorial Team · 4 min read